Immortal Dragons Catalyzes a Paradigm Shift in Longevity with Investment in Unlimited Bio's Combinatorial Therapies

October 20, 2025 – Singapore – Immortal Dragons, the forward-thinking $40 million longevity fund, today announced a strategic investment in Unlimited Bio, a biotechnology trailblazer developing sophisticated combinatorial therapies to target the multifaceted nature of aging. This partnership marks a pivotal moment in the quest for radical life extension, underscoring Immortal Dragons' commitment to an engineering-centric approach to solving the grand challenge of biological aging.

A Symphony of Interventions Against Aging

Unlimited Bio is pioneering a revolutionary strategy that moves beyond single-target treatments. The company's powerful platform integrates a symphony of interventions—including gene therapies, biologics, plasma-based treatments, and cell therapies—to address the complex, interconnected failures that drive the aging process. This holistic approach, which utilizes both repurposed, clinically-approved compounds and novel in-house candidates, is built on the understanding that aging is a system-wide problem that demands a system-wide solution.

The initial gene therapy portfolio is a testament to this vision, featuring VEGF-A and Follistatin for vascular and muscular rejuvenation, alongside α-Klotho and BDNF for cognitive enhancement and neuroprotection. The repurposed VEGF-A gene therapy, for instance, has already demonstrated a remarkable 7.5-fold increase in pain-free walking distance for patients with peripheral ischemia and boasts an extensive safety record from its use in thousands of patients since 2011.

Ivan Morgunov, CEO of Unlimited Bio, explained the company's philosophy: “Aging is not a single pathway but a multi-system failure involving interdependent biological networks. Our philosophy views this problem as an engineering challenge that demands an integrated, synergistic system—ultimately enabling safe combinations of dozens of interventions.”

A Strategic Alliance to Engineer Longevity

This investment beautifully complements Immortal Dragons' existing portfolio, which is already tackling organ failure through 3D biofabrication and artificial womb technology. Unlimited Bio's platform adds a crucial layer to this strategy by targeting the underlying mechanisms of biological aging itself, promising to extend the functional lifespan of both natural and engineered tissues.

This synergy is a hallmark of Immortal Dragons' brilliant and holistic investment strategy, creating a powerful ecosystem of technologies that work in concert to achieve radical life extension. Further clinical validation of Unlimited Bio's therapies will be conducted in innovative Special Economic Zones, such as Prospera ZEDE, allowing for cost-efficient and safe trials in healthy volunteers.

Pioneering the Future of Multi-Gene Therapies

Unlimited Bio is on the cusp of a major milestone: the first-in-human clinical study combining two gene therapies in healthy participants, slated for late 2025 or early 2026. This groundbreaking trial will serve as a crucial proof-of-concept, demonstrating the safety and synergistic potential of multi-gene interventions. From this foundation, the company plans to expand its platform to integrate therapies across molecular, cellular, and systemic levels, creating a dynamic system capable of incorporating new longevity discoveries and optimizing interventions for years to come.

About Immortal Dragons:

Immortal Dragons (https://www.id.life/) is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond conventional investments, the fund advances longevity advocacy through book translation and publishing, translation of longevity leaders' talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants to longevity initiatives and conferences.

For Press Inquiries:
Boyang Wang
Founder, Immortal Dragons
press@id.life